3.9 Article

β-Blocker Continuation After Noncardiac Surgery A Report From the Surgical Care and Outcomes Assessment Program

期刊

ARCHIVES OF SURGERY
卷 147, 期 5, 页码 467-473

出版社

AMER MEDICAL ASSOC
DOI: 10.1001/archsurg.2011.1698

关键词

-

类别

资金

  1. Washington Life Science Discovery Fund
  2. Agency for Healthcare Research and Quality [1 R01 HS 20025-01]

向作者/读者索取更多资源

Background: Despite limited evidence of effect, beta-blocker continuation has become a national quality improvement metric. Objective: To determine the effect of beta-blocker continuation on outcomes in patients undergoing elective noncardiac surgery. Design, Setting, and Patients: The Surgical Care and Outcomes Assessment Program is a Washington quality improvement benchmarking initiative based on clinical data from more than 55 hospitals. Linking Surgical Care and Outcomes Assessment Program data to Washington's hospital admission and vital status registries, we studied patients undergoing elective colorectal and bariatric surgical procedures at 38 hospitals between January 1, 2008, and December 31, 2009. Main Outcome Measures: Mortality, cardiac events, and the combined adverse event of cardiac events and/or mortality. Results: Of 8431 patients, 23.5% were taking beta-blockers prior to surgery (mean [SD] age, 61.9 [13.7] years; 63.0% were women). Treatment with beta-blockers was continued on the day of surgery and during the postoperative period in 66.0% of patients. Continuation of beta-blockers both on the day of surgery and postoperatively improved from 57.2% in the first quarter of 2008 to 71.3% in the fourth quarter of 2009 (P value <.001). After adjusting for risk characteristics, failure to continue beta-blocker treatment was associated with a nearly 2-fold risk of 90-day combined adverse event (odds ratio, 1.97; 95% CI, 1.19-3.26). The odds were even greater among patients with higher cardiac risk (odds ratio, 5.91; 95% CI, 1.40-25.00). The odds of combined adverse events continued to be elevated 1 year postoperatively (odds ratio, 1.66; 95% CI, 1.08-2.55). Conclusions: beta-Blocker continuation on the day of and after surgery was associated with fewer cardiac events and lower 90-day mortality. A focus on beta-blocker continuation is a worthwhile quality improvement target and should improve patient outcomes.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.9
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据